2026-07-03 · metformin, type 2 diabetes, prediabetes, PCOS, antipsychotic-induced weight gain, GLP-1 · 19 min read

Does metformin cause weight loss?

Modestly and inconsistently. The cleanest human data come from the Diabetes Prevention Program (Diabetes Prevention Program Research Group 2002, New England Journal of Medicine), where 850 mg twice daily produced a mean weight loss of about 2.1 kg over 2.8 years compared with 0.1 kg on placebo, and from Salpeter 2008 (American Journal of Medicine), a meta-analysis of 41 trials that found a mean 2 to 3 kg placebo-adjusted weight loss across mixed populations. That effect plateaus by roughly six months and reverses if the drug is stopped. It is real but small. Metformin is a first-line drug in type 2 diabetes because of its glycemic and cardiovascular record (ADA 2024 Standards of Care), not because of the scale. Anyone expecting GLP-1-sized weight loss — 10 to 20 percent of body weight — will be disappointed. Anyone weighing an anchor drug that will not cause the weight gain of a sulfonylurea or insulin has a good option.

How much weight will I lose on metformin?

In the DPP trial, adults with prediabetes and BMI around 34 lost about 2.1 kg on 850 mg twice daily over nearly three years versus 0.1 kg on placebo (Diabetes Prevention Program Research Group 2002). In Jarskog 2013 (American Journal of Psychiatry), adults on antipsychotics with weight gain lost about 3 kg more than placebo at 16 weeks on 500 to 2,000 mg per day. In Salpeter 2008 (American Journal of Medicine), the pooled placebo-adjusted effect across 41 trials was 2 to 3 kg. The realistic expectation is 1.5 to 3 kg over three to six months, with slower drift afterward. The effect is larger in adults who are heavier at baseline, on higher doses, and paired with lifestyle change. It is smaller in the older, thinner, and already-active. Metformin will not substitute for a 500 kcal/day deficit.

How long until metformin starts working for weight?

Any weight change usually appears in the first three months and plateaus by six months. Aroda 2016 (Journal of Clinical Endocrinology and Metabolism) followed DPP participants for years and showed the metformin arm held roughly 2 kg of weight loss at 10 years, but the vast majority of the loss happened early. Do not judge metformin by month one. Titration matters: most prescribers start 500 mg with dinner for a week, then 500 mg twice daily, then 1,000 mg twice daily over three to four weeks to reduce GI side effects. If weight is going to move on metformin, it will start moving within 8 to 12 weeks of reaching a therapeutic 1,500 to 2,000 mg per day dose. If nothing has changed at six months on a full dose, more metformin is not the answer — the conversation is about adding a GLP-1, an SGLT-2 inhibitor, or intensifying lifestyle work.

Should I take metformin if I do not have diabetes?

Only for a specific reason. The evidence for using metformin without diabetes is strongest in prediabetes with elevated risk (Diabetes Prevention Program Research Group 2002), in PCOS with insulin-resistance or menstrual-irregularity endpoints (ESHRE 2023 international PCOS guideline), in antipsychotic-induced weight gain (Jarskog 2013, American Journal of Psychiatry; Correll 2020, World Psychiatry), and in prior gestational diabetes with residual metabolic risk (Ratner 2008, Journal of Clinical Endocrinology and Metabolism). Metformin is not FDA-approved as a weight-loss drug, and neither the ADA nor the AACE endorses it as a stand-alone obesity treatment. Prescribing off-label for weight only in an otherwise metabolically healthy adult is a conversation to have honestly with a prescriber, not a self-directed decision — and it will not deliver GLP-1-sized results.

Is metformin safe long-term?

The safety record after nearly 70 years is unusually strong. Salpeter 2010 (Cochrane) found no excess lactic acidosis risk versus other diabetes therapies in adults with normal or moderately reduced kidney function. UKPDS 34 (UK Prospective Diabetes Study Group 1998, Lancet) followed adults with overweight type 2 diabetes for 10 years and reported a mortality benefit compared with conventional therapy. The two long-term issues that matter are B12 depletion and kidney-function limits. Aroda 2016 documented B12 deficiency in 4.3 percent of DPP metformin users at 5 years versus 2.3 percent on placebo, rising to 5.8 percent versus 2.4 percent at 13 years. The FDA 2016 labelling change moved dose adjustment from creatinine to eGFR: safe to eGFR 30, cap at 1,000 mg per day between eGFR 30 and 45, do not start below eGFR 45, stop below 30.

Does metformin deplete B12?

Yes, mildly and predictably over years, and yes, you should be screened. Aroda 2016 (Journal of Clinical Endocrinology and Metabolism) is the definitive follow-up: in the Diabetes Prevention Program Outcomes Study, B12 deficiency was 4.3 percent in the metformin arm versus 2.3 percent in placebo at 5 years, and 5.8 percent versus 2.4 percent at 13 years. Reinstatler 2012 (Diabetes Care) reported a similar prevalence signal in a broader cross-section. The mechanism is calcium-dependent B12 absorption in the terminal ileum, which metformin partially disrupts. The practical rule is an annual serum B12 after year two on metformin, with symptom screening for paresthesia, gait instability, or macrocytic anemia. Repletion is straightforward — 1,000 mcg oral cyanocobalamin daily is usually sufficient. See our guide on vitamin B12 deficiency and weight loss for the fuller repletion pathway.

Can I take metformin with a GLP-1?

Yes, and the combination is common. Nauck 2020 (Diabetes, Obesity and Metabolism) reviewed the head-to-head and combination evidence and found GLP-1 monotherapy produces greater weight loss than metformin monotherapy, and the combination is additive without a clinically important interaction. The ADA 2024 Standards of Care position metformin as a background anchor with a GLP-1 layered on when weight, A1c, or cardiovascular risk warrants intensification. Both drugs share GI side effects — nausea, diarrhea, occasional cramping — so most prescribers hold metformin titration until the GLP-1 is at a tolerated dose. If only one drug can continue for cost or tolerability reasons, the GLP-1 usually delivers more weight and cardiovascular benefit, but the decision depends on individual insurance and history. This is a prescriber conversation, not a unilateral swap.

Does metformin help PCOS weight?

Partially, and best as an adjunct to lifestyle rather than a solo treatment. The 2023 ESHRE international PCOS guideline positions metformin as a second-line adjunct to lifestyle for metabolic and menstrual endpoints, not as a first-line fertility drug. Legro 2007 (New England Journal of Medicine, the PPCOS trial) compared clomiphene, metformin, and combination for ovulation induction and found metformin lost the fertility endpoint to clomiphene — but preserved a metabolic role for insulin resistance, menstrual regularity, and moderate weight support. Practical expectations: 2 to 4 kg of weight-related benefit over 6 to 12 months when paired with structured lifestyle change, small A1c and insulin-resistance improvement, and better menstrual cycles in a subset. Metformin will not fix PCOS on its own, and it does not replace GLP-1 therapy where obesity is the dominant driver. See our PCOS and weight loss guide for the full framework.

When should I stop metformin?

Never as a self-directed decision. Reasons to reassess are an eGFR drop below 45 with a plan to dose-cap or discontinue below 30 (FDA 2016 labelling), severe or persistent GI intolerance that does not respond to switching to extended-release or reducing the dose, symptomatic B12 deficiency, active pregnancy in a PCOS user (metformin restores ovulation and unplanned pregnancy can occur), or a switch to GLP-1 monotherapy when insurance or side effects force a choice. Do not stop metformin because you have lost weight — the glycemic and cardiovascular benefits do not evaporate on weight loss, and stopping without a plan risks A1c drift. Any switch, hold, or discontinuation is a prescriber conversation, ideally with an updated A1c and eGFR in hand within the last three months.

Metformin and Weight: What It Does, What It Doesn’t, and When It Helps

Metformin is the most-prescribed diabetes medication in the world — roughly 78 million US prescriptions filled in 2023 (IQVIA), and a first-line drug for type 2 diabetes in every major guideline including the ADA 2024 Standards of Care. It is also the drug most often mistaken for a weight-loss medication. It is not one. The Diabetes Prevention Program Research Group 2002 (New England Journal of Medicine) — the largest randomised trial of metformin in adults at risk for diabetes — reported a mean weight loss of 2.1 kg on 850 mg twice daily versus 0.1 kg on placebo over 2.8 years, and Salpeter 2008 (American Journal of Medicine), a meta-analysis of 41 trials, pooled a placebo-adjusted effect of 2 to 3 kg across mixed populations. That effect plateaus by six months and reverses on discontinuation.

The honest framing: metformin is not a weight-loss drug and no credible trial has ever positioned it as one. What it is — an anchor drug that improves A1c, lowers cardiovascular events (UKPDS 34, Lancet 1998), does not cause the weight gain of sulfonylureas or insulin, has a decades-long safety record (Salpeter 2010 Cochrane), and layers cleanly onto GLP-1 therapy (Nauck 2020, Diabetes, Obesity and Metabolism) — is genuinely useful in prediabetes where lifestyle alone has not moved the needle, in PCOS for menstrual and metabolic endpoints (ESHRE 2023 international PCOS guideline), in antipsychotic-induced weight gain where the placebo-adjusted 3 kg effect at 16 weeks (Jarskog 2013, American Journal of Psychiatry) matters clinically, and in type 2 diabetes where it remains a first-line drug in the era of GLP-1 and SGLT-2 inhibitors. This guide covers who benefits, how the drug actually works, dose and titration, the B12 monitoring problem, kidney-function limits, and how metformin sits alongside modern GLP-1 therapy.

Quick stats

• 78 million US metformin prescriptions filled in 2023 (IQVIA prescription data).
• DPP 2002 mean weight loss: 2.1 kg on 850 mg twice daily versus 0.1 kg placebo at 2.8 years (Diabetes Prevention Program Research Group 2002, New England Journal of Medicine).
• Jarskog 2013 antipsychotic add-on: 3 kg placebo-adjusted weight loss at 16 weeks (American Journal of Psychiatry).
• Aroda 2016 B12 depletion: 5.8 percent deficiency at 13 years on metformin versus 2.4 percent on placebo (Journal of Clinical Endocrinology and Metabolism).
• ADA 2024 Standards of Care: metformin remains first-line pharmacotherapy for type 2 diabetes.
• FDA 2016 eGFR-based dose adjustment: safe to eGFR 30, dose-cap at 1,000 mg/day between 30 and 45, do not start below 45, stop below 30.
• 1-800-222-1222 — US Poison Control for accidental over-ingestion in a child or adult.

How metformin is organised

Metformin comes in three main formulations with the same active drug and broadly the same A1c effect, but different tolerability profiles and dosing rhythms.

Why metformin works (and doesn’t) for weight

Four mechanistic threads describe how metformin nudges body weight, and one of them describes why it is not a weight-loss drug in a metabolically healthy adult.

1. Hepatic AMPK activation and gluconeogenesis suppression

Bailey 2019 (New England Journal of Medicine) and Foretz 2019 (Nature Reviews Endocrinology) describe the primary mechanism: metformin partially inhibits mitochondrial complex 1 in the liver, raises the AMP:ATP ratio, activates AMPK, and suppresses hepatic gluconeogenesis. That lowers fasting glucose without provoking hypoglycemia and reduces the insulin secretion needed to hold blood sugar in range. Lower ambient insulin has downstream metabolic effects that indirectly support fat oxidation, but the primary target is glucose, not fat.

2. Intestinal action, microbiome, and bile-acid signalling

Foretz 2019 and Wu 2017 (Nature Medicine) show that a substantial fraction of metformin’s glycemic effect happens in the gut, not the liver. The drug alters intestinal glucose handling, shifts the gut microbiome toward Akkermansia muciniphila-enriched communities, and modulates bile-acid signalling through FXR and TGR5 pathways. The intestinal action helps explain why the delayed-release (gut-restricted) formulation preserves A1c effect while lowering systemic exposure (Buse 2016).

3. GDF15 → GFRAL hindbrain appetite suppression

Coll 2020 (Nature) and Day 2019 (Nature Medicine) identified the appetite mechanism: metformin raises circulating GDF15, which acts on the GFRAL receptor in the hindbrain to reduce food intake in a subset of patients. This is the closest metformin comes to a “GLP-1-like” mechanism, but the effect size is far smaller. GDF15 elevation explains part of the mild appetite blunting some patients report and part of the modest weight-loss signal in the DPP.

4. What metformin is not

Metformin is not a leptin analogue, not a GLP-1 receptor agonist, and not a substitute for a 500 kcal/day energy deficit or a structured activity plan. Its weight effect plateaus by roughly six months, does not stack indefinitely, and reverses within weeks of discontinuation. Anyone expecting semaglutide- or tirzepatide-scale results — 10 to 20 percent of body weight — will be disappointed. Anyone using metformin as an anchor while a real weight plan is running has a durable, cheap, and safe tool.

Dose-response and time-course

The metformin weight and A1c effect front-loads in the first six months and drifts modestly for years afterward. B12 status quietly declines over the same window.

5-step protocol: screening, titration, and monitoring

This is the practical clinical rhythm most prescribers use in 2026. It matches ADA 2024, ESHRE 2023, and FDA 2016 labelling.

Step 1: Confirm the indication

Metformin is appropriate for type 2 diabetes as first-line therapy (ADA 2024), for prediabetes with elevated risk especially BMI ≥ 35 or age < 60 or prior gestational diabetes (per DPP), for PCOS with metabolic or menstrual endpoints (ESHRE 2023), for antipsychotic-induced weight gain as a first-line pharmacologic add-on (Correll 2020, World Psychiatry), and for postpartum after gestational diabetes to reduce incident type 2 diabetes (Ratner 2008). Off-label prescription for weight alone in a metabolically healthy adult should be a deliberate prescriber conversation, not a default.

Step 2: Baseline labs

Before starting, most prescribers check A1c, a comprehensive metabolic panel with eGFR, a baseline serum B12, and a thyroid panel where clinically indicated. Document any history of GI intolerance, chronic kidney disease, hepatic impairment, alcohol-use disorder, or recent contrast-media exposure. In pediatric prescribing (age 10 and above), follow the Rojas 2013 dosing and monitoring pattern.

Step 3: Titrate slowly to reduce GI intolerance

The single most common reason metformin gets abandoned is a too-fast start. The tolerated titration is 500 mg with dinner × 1 week → 500 mg twice daily × 1 week → 1,000 mg twice daily over 3 to 4 weeks, always with food. If GI intolerance persists at 1,000 mg twice daily IR, switch to extended-release (XR / ER) at 500 to 2,000 mg once daily with dinner — Blonde 2004 (Current Medical Research and Opinion) documented non-inferior A1c effect with fewer GI complaints on ER.

Step 4: Layer, do not stack blindly

Metformin combines cleanly with GLP-1 receptor agonists (Nauck 2020), SGLT-2 inhibitors (Zinman 2015, EMPA-REG New England Journal of Medicine), and basal insulin without pharmacologic redundancy. Sulfonylureas are usually the wrong add for a patient with weight goals — the sulfonylurea drives weight gain and hypoglycemia risk without matching the CV benefit of a GLP-1 or SGLT-2. See our GLP-1 medications compared and prescription weight loss medications guides for the layering logic.

Step 5: Annual B12 after year 2, eGFR every 6 to 12 months

Follow Aroda 2016 for B12: annual serum B12 after year two on metformin, symptom screen at every visit (paresthesia, gait instability, macrocytic anemia), and repletion with 1,000 mcg oral cyanocobalamin daily where deficiency is documented. Follow FDA 2016 for kidney monitoring: eGFR every 6 to 12 months, dose-cap at 1,000 mg/day at eGFR 30 to 45, do not start below 45, stop below 30. Hold metformin for 48 hours around iodinated contrast studies in adults with eGFR under 60.

What metformin actually does — compared to alternatives

Prediabetes and the Diabetes Prevention Program

The DPP (Diabetes Prevention Program Research Group 2002, New England Journal of Medicine) is the single most important metformin trial for non-diabetic weight readers. It randomised 3,234 adults with impaired glucose tolerance (BMI ≥ 24, fasting glucose 95 to 125, 2-hour post-load 140 to 199) to intensive lifestyle intervention, metformin 850 mg twice daily, or placebo. At 2.8 years, incident type 2 diabetes was reduced 58 percent in the lifestyle arm and 31 percent in the metformin arm compared with placebo, and mean weight loss was 7 kg (lifestyle) versus 2.1 kg (metformin) versus 0.1 kg (placebo).

The Diabetes Prevention Program Outcomes Study 2012 (Diabetes Care) followed the same cohort out to 10 years. The metformin arm held roughly 2 kg of weight loss and preserved a substantial fraction of the type-2-diabetes prevention benefit — the durability signal that makes metformin worth using in prediabetes. Ratner 2008 (Journal of Clinical Endocrinology and Metabolism) analysed the subgroup of women with prior gestational diabetes and reported a 50 percent reduction in incident type 2 diabetes on metformin — the strongest prediabetes-prevention signal in the trial. Metformin is not FDA-approved as a diabetes-prevention drug but is broadly used off-label in this population, especially BMI ≥ 35, age < 60, fasting glucose 110 to 125, or prior gestational diabetes. See prediabetes and weight loss and gestational diabetes and weight loss for the fuller framing.

PCOS: an adjunct, not a fertility-first drug

Metformin has been used in PCOS for two decades, and the honest state of the evidence has narrowed since the early enthusiasm. Legro 2007 (New England Journal of Medicine), the PPCOS trial, randomised anovulatory women with PCOS to clomiphene alone, metformin alone, or combination for ovulation induction — clomiphene beat metformin decisively on the live-birth endpoint. Palomba 2004 (Journal of Clinical Endocrinology and Metabolism) showed a role in restoring menstrual regularity, and the ESHRE 2023 international PCOS guideline positions metformin as a second-line adjunct to lifestyle for metabolic and menstrual endpoints — not a fertility-first drug.

Expected effects on weight in PCOS are modest — 2 to 4 kg over 6 to 12 months when paired with structured lifestyle change — and improvements in insulin resistance and menstrual cyclicity are usually the larger clinical wins. Metformin does not substitute for a GLP-1 in PCOS with obesity, and it is not a substitute for lifestyle change. See PCOS and weight loss for the full treatment framework.

Antipsychotic-induced weight gain

This is one of the strongest use cases for metformin outside diabetes. Second-generation antipsychotics — olanzapine, clozapine, quetiapine, risperidone — cause substantial weight gain and metabolic disturbance that drives medication non-adherence and long-term cardiovascular risk. Jarskog 2013 (American Journal of Psychiatry), the pivotal randomised controlled trial, tested metformin 500 to 2,000 mg per day versus placebo in 148 adults with schizophrenia on antipsychotics with clinically significant weight gain — the metformin arm lost ~3 kg more than placebo at 16 weeks, alongside waist-circumference and insulin-resistance improvements.

Correll 2020 (World Psychiatry) formalised the position: metformin is the first-line pharmacologic add-on for antipsychotic-induced metabolic burden. Titration is standard — 500 mg with dinner, then 500 mg twice daily, then 1,000 mg twice daily — with attention to GI tolerability in a population already handling antipsychotic side effects. Do not stop the antipsychotic to fix the weight; the psychiatric benefit of the antipsychotic is not replaceable, and metformin is the anchor drug that lets the psychiatric plan continue. See our companion guide on antipsychotics and weight changes for the broader framework.

Postpartum after gestational diabetes

Adults with prior gestational diabetes carry a lifetime type 2 diabetes risk of 50 to 60 percent. Ratner 2008 (Journal of Clinical Endocrinology and Metabolism), analysing the DPP subgroup with prior GDM, reported a 50 percent reduction in incident type 2 diabetes on metformin versus placebo — one of the strongest prevention signals in any DPP subgroup. The clinical rhythm is a fasting glucose or A1c at the 6-week postpartum visit, an OGTT at 12 weeks if the initial screen is normal, and honest counselling that metformin is a durable adjunct to breastfeeding, weight loss, and cardiometabolic follow-through. See gestational diabetes and weight loss for the pre-conception through postpartum arc.

Metformin plus GLP-1: the modern combination

Nauck 2020 (Diabetes, Obesity and Metabolism) reviewed the head-to-head and combination evidence. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — deliver substantially more weight loss than metformin as monotherapy (10 to 22 percent versus 2 to 3 percent of body weight). The combination is additive without a clinically important pharmacologic interaction, and both drugs share the GI side-effect profile (nausea, diarrhea, occasional cramping). Most prescribers hold metformin titration until the GLP-1 is at a tolerated dose.

If cost, insurance, or side effects force a choice between metformin and a GLP-1 in an adult with obesity and type 2 diabetes, the GLP-1 usually delivers more weight loss and better cardiovascular outcomes — but the ADA 2024 Standards of Care still position metformin as a legitimate first-line anchor when a GLP-1 is inaccessible. See GLP-1 weight loss overview and GLP-1 cost and insurance for the practical layering.

B12 depletion on long-term therapy

Aroda 2016 (Journal of Clinical Endocrinology and Metabolism) is the definitive long-term follow-up of B12 status in the Diabetes Prevention Program Outcomes Study. At 5 years, B12 deficiency was 4.3 percent on metformin versus 2.3 percent on placebo; at 13 years, 5.8 percent versus 2.4 percent. Reinstatler 2012 (Diabetes Care) reported a similar prevalence signal in a broader NHANES-based cross-section. The mechanism is calcium-dependent B12 absorption in the terminal ileum, which metformin partially disrupts.

The practical rule is annual serum B12 after year two on metformin, with symptom screening for paresthesia, gait instability, macrocytic anemia, or unexplained fatigue at every visit. Repletion is usually 1,000 mcg oral cyanocobalamin daily; intramuscular replacement is reserved for symptomatic deficiency or malabsorption. See vitamin B12 deficiency and weight loss for the fuller diagnostic and repletion pathway.

Kidney-function limits and lactic acidosis

Salpeter 2010 (Cochrane) pooled 347 comparative trials and found no excess lactic acidosis on metformin versus other diabetes therapies in adults with normal or moderately reduced kidney function. The historical fear of lactic acidosis on metformin stemmed from phenformin, a related but structurally distinct drug that was withdrawn in the 1970s. The FDA 2016 labelling change codified modern practice: dose adjustment by eGFR, not creatinine — safe to eGFR 30, dose-cap at 1,000 mg/day between eGFR 30 and 45, do not start below eGFR 45, stop below 30.

The remaining risk windows are acute kidney injury, sepsis, dehydration, iodinated-contrast studies, and major surgery — hold metformin for 48 hours around these events, and restart once renal function is confirmed stable. Alcohol-use disorder in the setting of chronic metformin adds a small independent lactic acidosis signal; honest discussion of alcohol intake is part of the risk-benefit conversation.

Red flags — when to see a doctor

Some findings are not routine and warrant same-week or same-day evaluation.

• Symptomatic B12 deficiency — new paresthesia, gait ataxia, macrocytic anemia, or unexplained fatigue in an adult on metformin ≥ 2 years — serum B12 with methylmalonic acid confirmation and repletion (Aroda 2016).
• Lactic acidosis — muscle pain, unusual sleepiness, deep and rapid breathing, abdominal pain, or hypothermia, especially in the setting of acute kidney injury, sepsis, contrast studies, or heavy alcohol use — same-day ER evaluation.
• Severe or persistent GI intolerance — beyond the first 4 weeks of titration — is a signal to switch to extended-release, reduce the dose, or reassess the indication rather than push through.
• Unintended pregnancy in PCOS therapy — metformin restores ovulation and can normalise cycles; anyone on metformin for PCOS should have a contraception plan if pregnancy is not desired.
• Accidental ingestion in a child — call 1-800-222-1222 (US Poison Control) for immediate guidance; metformin has a wide therapeutic window but pediatric ingestion still warrants professional advice.
• Hypoglycemia — metformin alone does not cause hypoglycemia; low blood sugars on a metformin regimen usually mean an added sulfonylurea, insulin, or GLP-1 dose is out of proportion to intake, and the layering plan needs review.

How this connects to the rest of the site

For the diagnostic and lifestyle context, see diabetes and weight loss, prediabetes and weight loss, gestational diabetes and weight loss, and type 1 diabetes and weight loss. For the mechanism-level story, see insulin resistance and weight loss and metabolic syndrome and weight loss. For the specific reproductive-endocrine and psychiatric contexts, see PCOS and weight loss and antipsychotics and weight changes. For the B12 monitoring pathway, see vitamin B12 deficiency and weight loss. For the drug-class comparisons and safety framing, see GLP-1 medications compared, prescription weight loss medications, and weight loss drug safety.

Metformin and weight FAQ

Does metformin cause weight loss? Modestly — about 2 to 3 kg placebo-adjusted, plateauing by 6 months (DPP 2002; Salpeter 2008).

How long until it works? Any change appears in the first 3 months; if nothing has moved at 6 months on 2,000 mg/day, more metformin is not the answer.

Should I take it without diabetes? Only for a specific indication — prediabetes, PCOS, antipsychotic-induced weight gain, or postpartum after GDM.

Is it safe long-term? Yes, with annual B12 after year 2 and eGFR monitoring per FDA 2016 labelling.

Does it deplete B12? Yes, 4 to 6 percent deficiency at 5 to 13 years (Aroda 2016); annual serum B12 after year 2.

Can I take it with a GLP-1? Yes — the combination is common and additive (Nauck 2020).

Does it help PCOS weight? Modestly (2 to 4 kg) and best as an adjunct to lifestyle (ESHRE 2023).

When should I stop? Never as a self-directed decision — eGFR drop below 45, severe GI intolerance, or a prescriber-coordinated switch to GLP-1 monotherapy are the usual reasons.